MA56043A - Dérivés hétérocycliques fusionnés - Google Patents

Dérivés hétérocycliques fusionnés

Info

Publication number
MA56043A
MA56043A MA056043A MA56043A MA56043A MA 56043 A MA56043 A MA 56043A MA 056043 A MA056043 A MA 056043A MA 56043 A MA56043 A MA 56043A MA 56043 A MA56043 A MA 56043A
Authority
MA
Morocco
Prior art keywords
fused heterocyclic
heterocyclic derivatives
derivatives
fused
heterocyclic
Prior art date
Application number
MA056043A
Other languages
English (en)
French (fr)
Inventor
Jan Martin Berke
Zhanling Cheng
Gang Deng
Lindsey Graham Deratt
Sandrine Céline Grosse
Lili Hu
Yimin Jiang
Tim Hugo Maria Jonckers
Bart Rudolf Romanie Kesteleyn
Scott D Kuduk
Morgan Charles R Lecomte
Lamenca Carolina Martinez
Serge Maria Aloysius Pieters
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Wim Gaston Verschueren
Yanping Xu
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71741889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA56043(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56043A publication Critical patent/MA56043A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056043A 2019-05-28 2020-05-27 Dérivés hétérocycliques fusionnés MA56043A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853533P 2019-05-28 2019-05-28
EP19176933 2019-05-28
CN2020085720 2020-04-20

Publications (1)

Publication Number Publication Date
MA56043A true MA56043A (fr) 2022-04-06

Family

ID=71741889

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056043A MA56043A (fr) 2019-05-28 2020-05-27 Dérivés hétérocycliques fusionnés

Country Status (19)

Country Link
EP (1) EP3976617B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022535734A (cg-RX-API-DMAC7.html)
KR (1) KR20220012913A (cg-RX-API-DMAC7.html)
CN (1) CN113906028A (cg-RX-API-DMAC7.html)
AU (1) AU2020285718A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022889A8 (cg-RX-API-DMAC7.html)
CA (1) CA3138168A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003155A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016433A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210666A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000230A (cg-RX-API-DMAC7.html)
IL (1) IL288322A (cg-RX-API-DMAC7.html)
JO (1) JOP20210313A1 (cg-RX-API-DMAC7.html)
MA (1) MA56043A (cg-RX-API-DMAC7.html)
MX (1) MX2021014575A (cg-RX-API-DMAC7.html)
PE (1) PE20220767A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552974A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202113167QA (cg-RX-API-DMAC7.html)
WO (1) WO2020243135A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022116999A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives and their use in the treatment of hbv infection
WO2022116998A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives as hbv inhibitors
TW202237617A (zh) * 2020-12-02 2022-10-01 愛爾蘭商健生科學愛爾蘭無限公司 稠合雜環衍生物
AR126049A1 (es) 2021-06-02 2023-09-06 Janssen Sciences Ireland Unlimited Co Derivados heterocíclicos condensados
CA3218641A1 (en) * 2021-06-02 2022-12-08 Chunliang Lu Fused heterocyclic derivatives
WO2024114709A1 (en) * 2022-12-01 2024-06-06 Janssen Sciences Ireland Unlimited Company A crystal form of a fused heterocycle derivative compound
WO2024140851A1 (zh) * 2022-12-28 2024-07-04 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2993174A1 (en) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
WO2016109689A2 (en) * 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
CA3029566A1 (en) * 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
TW201806956A (zh) * 2016-06-29 2018-03-01 諾維拉治療公司 二氮呯酮衍生物及治療b型肝炎感染之方法
US20220306647A1 (en) * 2019-04-30 2022-09-29 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitus b virus (hbv)

Also Published As

Publication number Publication date
EP3976617B1 (en) 2025-04-23
JOP20210313A1 (ar) 2021-11-25
CL2021003155A1 (es) 2022-07-22
MX2021014575A (es) 2022-05-24
WO2020243135A1 (en) 2020-12-03
PH12021552974A1 (en) 2022-07-11
AU2020285718A1 (en) 2022-02-03
CR20210666A (es) 2022-03-11
PE20220767A1 (es) 2022-05-16
EP3976617A1 (en) 2022-04-06
CO2021016433A2 (es) 2021-12-10
BR112021022889A8 (pt) 2024-03-05
DOP2021000230A (es) 2022-05-31
KR20220012913A (ko) 2022-02-04
SG11202113167QA (en) 2021-12-30
CN113906028A (zh) 2022-01-07
BR112021022889A2 (pt) 2022-01-04
CA3138168A1 (en) 2020-12-03
IL288322A (en) 2022-01-01
JP2022535734A (ja) 2022-08-10

Similar Documents

Publication Publication Date Title
IL283333A (en) New heterocyclic compounds
PT3958977T (pt) Derivados de camptotecina
IL292161A (en) New methylquinazolinone derivatives
LT3830085T (lt) Deuterinti lanifibranoro dariniai
IL279977A (en) Anthelminthic heterocyclic compounds
EP4061813C0 (en) PYRROLIDINE DERIVATIVES
EP4013751C0 (en) 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES
EP4077334C0 (en) FUROINDAZOLE DERIVATIVES
EP4744661A2 (en) NEW PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
DK3768669T3 (da) Piperazinazaspiroderivater
IL288322A (en) Condensed heterocyclic hists
PL4301748T3 (pl) Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu
ZA202106024B (en) Heterocyclic derivatives
DK3898637T3 (da) Rapamycin-derivater
MA54521A (fr) Dérivés d'oxopyridine substitués
EP3884940A4 (en) Novel imidazole derivative
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
IL304774A (en) Enhanced sophorolipid derivatives
EP3822270A4 (en) NEW HETEROCYCLIC DERIVATIVE
EP3813522C0 (en) TAUOPATHY MODELS
EP3867248C0 (en) PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS
DK3782986T3 (da) Heterocyklisk forbindelse
DK3796975T3 (da) Sulfonylaminobenzamidderivater
DK4396183T3 (da) Substituerede s-alaninatderivater